Related Experiment Video
Updated: Jul 1, 2026
Laboratory Administration of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): Technique, Targeting, and Considerations
Published on: January 7, 2019
Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Swallowing Function in Post-stroke Dysphagia: A
E Chang1, Yujuan Jiang2, Jiongmei Wang1
1Department of Rehabilitation Medicine, Cangzhou Central Hospital, Cangzhou, 061000, Hebei, China.
None:
Post-stroke dysphagia (PSD) is a common and disabling complication of stroke. Conventional swallowing rehabilitation provides limited benefit for patients with moderate-to-severe PSD, especially those with impaired neuromuscular activation. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a non-invasive neuromodulatory approach that may enhance swallowing recovery, yet its clinical efficacy and underlying mechanisms remain to be clarified. A total of 96 patients with PSD were randomly assigned to a control group (conventional swallowing rehabilitation) or a taVNS group (conventional rehabilitation + taVNS). After a 4-week intervention, 86 patients completed the study (Control: n = 44; taVNS: n = 42). Clinical swallowing outcomes (FOIS, SSA, PAS), swallowing-related surface electromyography (Aemg, Iemg, reverse activation proportion, EMG latency), and serum biomarkers (BDNF, GFAP, IL-6) were assessed before and after treatment. Both groups exhibited improved swallowing function after intervention; however, the taVNS group showed significantly greater improvement in FOIS (p < 0.001), SSA (p < 0.001), and PAS (p = 0.001) compared with the control group. The taVNS group also demonstrated larger increases in Aemg and Iemg, greater reductions in reverse activation proportion, and shorter EMG latency (all p < 0.05). Serum BDNF levels increased more prominently in the taVNS group, whereas GFAP and IL-6 levels showed significantly greater reductions (all p < 0.01), with large to moderate-large effect sizes for key outcomes (FOIS: Cohen's d = 0.69, 95%CI [0.42,0.82]; SSA: d = 0.64, 95%CI [-5.28,-1.74]; BDNF: d = 1.36, 95%CI [2.33,3.77]; IL-6: d = 0.91, 95%CI [-16.65,-7.99]). taVNS combined with conventional rehabilitation was associated with greater swallowing improvements. However, due to feasibility constraints in moderate-to-severe PSD patients, a sham control was not included; therefore, causal attribution specifically to vagus nerve activation remains preliminary. The observed changes in serum biomarkers (increased BDNF, decreased GFAP and IL-6) are exploratory parallel associations and do not constitute mechanistic proof of central nervous system effects.
